ADAM-Integrin Interactions: Potential Integrin Regulated Ectodomain Shedding Activity

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|11|7|837-847

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.11, Iss.7, 2005-03, pp. : 837-847

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Urokinase Receptor and Integrin Interactions

By  

Current Pharmaceutical Design, Vol. 9, Iss. 19, 2003-01 ,pp. : 1565-1574

Bentham Science Publishers

Access to resources Recommend Favorite

Ectodomain Shedding and Regulated Intracellular Proteolysis in the Central Nervous System

By  

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 10, Iss. 4, 2010-12 ,pp. : 337-359

Bentham Science Publishers

Access to resources Recommend Favorite

Cilengitide, an integrin antagonist, has shown potential in the treatment of malignant glioma

By  

Inpharma, Vol. 1, Iss. 1589, 2007-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Alpha 4 Integrin Antagonists

By  

Current Pharmaceutical Design, Vol. 8, Iss. 14, 2002-06 ,pp. : 1229-1253

Bentham Science Publishers

Access to resources Recommend Favorite

Integrin modulators: a patent review

By Kapp Tobias G   Rechenmacher Florian   Sobahi Tariq R   Kessler Horst  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 10, 2013-10 ,pp. : 1273-1295

Informa Healthcare

Access to resources Recommend Favorite